Within life sciences, we invest across two pillars: precision neuroscience and life sciences platforms.
In precision neuroscience, we fund a diversity of approaches across neurodegeneration, psychiatry and neurotech. Although we focus on disease modifying therapeutics, we fund companies across therapeutics, devices and diagnostics.
In life sciences platforms, we fund companies that transform the way we discover, develop, and deliver medicines of the future, like de novo platforms, regenerative medicine, computational biology, and provider operations.
Core to our strategy is a polymedicine approach to treat complex diseases that represent a significant burden to the mortality, morbidity, and quality of life of patients and economies. At this time, we do not invest in non-platform companies in oncology, cardiovascular, or rare diseases.